GreenLight Clinical and Taimei Technology Expand CRO Alliance to Enterprise-Wide AI Platform at AusBiotech 2026

• GreenLight Clinical (GLC), a physician-led contract research organization specializing in Phase I–III trials across oncology, ophthalmology, and rare diseases in Australia and the Asia-Pacific, and Taimei Technology (02576.HK), a global provider of AI-powered clinical development platforms serving 1,600+ biopharma organizations and CROs across 30+ countries, have formalized an expanded enterprise-wide strategic partnership at AusBiotech 2026 in Gold Coast, Australia — evolving a targeted 2024 EDC software engagement into a full trial lifecycle, AI automation, and collaborative central imaging alliance.

• The expanded roadmap will scale deployment across Taimei’s unified platform — building on proven gains from eCollect EDC, eBalance randomization, and eSafety safety management — to embed intelligent automation into routine CRO workflows, explore collaborative central imaging capabilities, and develop institutional memory features designed to compound speed and quality improvements across successive GLC-managed trials.

GreenLight Clinical (GLC), a physician-led contract research organization with operations across Australia and the broader Asia-Pacific region, and Taimei Technology (02576.HK), a leading global provider of AI-powered clinical development platforms, announced an expanded enterprise-wide strategic partnership on October 22, 2026, at AusBiotech 2026 in Gold Coast, Australia. The expanded agreement was formalized onsite by Taimei Technology Vice President Ben Cai, representing a deliberate evolution from a point-solution software engagement into an organization-wide alliance covering the full clinical trial lifecycle, AI-powered workflow automation, and collaborative central imaging capabilities.

The partnership originated in 2024 with GLC’s adoption of Taimei’s eCollect electronic data capture solution, subsequently expanding to include eBalance trial randomization and eSafety safety management. The 2026 expansion builds on demonstrable operational gains from those initial deployments, with GLC citing measurable improvements in data management and safety workflows as the foundation for scaling to a broader enterprise integration. Under the expanded roadmap, the partners will extend Taimei’s unified platform across GLC’s clinical operations, explore collaborative central imaging capabilities, embed protocol-aware intelligent automation into routine data and clinical workflows under medical oversight, and — over the longer term — develop institutional memory features that enable each completed study to compound performance improvements across future trials within the platform.

The model being built between GLC and Taimei reflects a structural shift in how physician-led specialty CROs are approaching AI in clinical operations. Rather than integrating discrete AI tools at individual workflow touchpoints, the collaboration is designed to create a single digital foundation across which operational data, clinical oversight, and AI-generated efficiencies co-exist and accumulate over time. Each trial managed on the platform generates data that feeds back into the system — improving site selection, protocol execution, data management, and safety monitoring for the studies that follow. For APAC-focused CRO sponsors partnering with GLC, the long-term implication is access to a CRO that is structurally improving its own operational precision with each completed study, without requiring sponsors to carry the infrastructure investment themselves.

Taimei Technology’s platform serves more than 1,600 biopharmaceutical organizations and CROs across 30+ countries and regions, supporting pharmaceutical R&D, safety surveillance, and commercialization from its integrated TrialOS digital cooperation platform. GreenLight Clinical conducts trials to ICH/GCP and ISO 9001:2015 standards across oncology, ophthalmology, and rare disease indications from Phase I through Phase III, with a particular focus on leveraging Australia’s regulatory framework and tax credit environment for early-phase and proof-of-concept programs.

“Sponsors today require clinical partners who think like physicians but execute with modern technological velocity. Having proven measurable gains with Taimei in data management and safety, expanding across the wider trial lifecycle, imaging, and AI workflows was our natural next step. Automating routine data workflows removes manual friction, allowing our medical and operational teams to focus squarely on clinical excellence and accelerated study delivery.”

Dr. Robert Lin, Chief Executive Officer, GreenLight Clinical